BiotechTube

Oral Encochleated Amphotericin B (CAMB) + Oral Encochleated Amphotericin B (CAMB)

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vulvovaginal Candidiases

Conditions

Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis, Yeast Infection Vaginal, Candidiasis, Vulvovaginal

Trial Timeline

Dec 1, 2019 → Dec 1, 2020

NCT ID
NCT03167957

About Oral Encochleated Amphotericin B (CAMB) + Oral Encochleated Amphotericin B (CAMB)

Oral Encochleated Amphotericin B (CAMB) + Oral Encochleated Amphotericin B (CAMB) is a phase 2 stage product being developed by Matinas Biopharma for Vulvovaginal Candidiases. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03167957. Target conditions include Vulvovaginal Candidiases, Yeast Infection, Vulvovaginitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03167957Phase 2Withdrawn

Competing Products

10 competing products in Vulvovaginal Candidiases

See all competitors
ProductCompanyStageHype Score
SHR8008 + FluconazoleJiangsu Hengrui MedicinePhase 3
77
SHR8008 capsule + Fluconazole capsuleJiangsu Hengrui MedicinePhase 3
77
Estradiol 10 MCG Vaginal Tablet [VAGIFEM] + Promestriene VaginalNovo NordiskPhase 3
76
FluconazolePfizerPhase 3
76
Clotrimazole vaginal tablet + FluconazoleBayerApproved
82
SCY-078 + FluconazoleScynexisPhase 2
44
IbrexafungerpScynexisPhase 3
69
Fluconazole Tablet + IBREXAFUNGERP + Placebo oral tabletScynexisPhase 3
69
IbrexafungerpScynexisPhase 1
25
Estradiol + PlaceboTherapeuticsMDPhase 3
69

Other Products from Matinas Biopharma

Placebo + MAT9001 (omega-3 pentaenoic acid)Phase 3
69
MAT2203 + Amphotericin BPhase 3
69
Oral Encochleated Amphotericin B (CAMB)Phase 2
44
Amphotericin BPhase 2
44
Omega 3 pentaenoic acid + icosapent ethylPhase 2
44